BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, June 8, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 27, 2020
View Archived Issues
Cross-reactive immunity helps antitumor response
Read More
How antidepressants inhibit fibrosis
Read More
Interim results from a phase I trial of FixVac RNA vaccine in patients with advanced melanoma
Read More
BBT-032 inhibits growth of the SARS-CoV-2 virus in preclinical studies
Read More
Expression Therapeutics developing gene therapy candidate for FHL3
Read More
TLR adjuvant makes for longer immune responses
Read More
Albireo presents new SLC10A2 and/or SLC10A1 inhibitors
Read More
DNA polymerase theta inhibitors identified at Ideaya Biosciences
Read More
Lilly discovers KCNQ2/3 channel activators
Read More
Capulus Therapeutics synthesizes new SREBP inhibitors
Read More
New IL-17A/IL-17RA interaction inhibitors patented by DiCE Molecules
Read More
Oncology Venture to advance stenoparib into clinical trials for COVID-19
Read More
MK-4710: a new potent, selective, brain-penetrant M4R PAM suitable for clinical development
Read More
Debiopharm begins phase I study of Debio-1124 for small cell carcinoma
Read More
Novartis details development of best-in-class LTA4 hydrolase inhibitor LYS-006
Read More
Conditional E.U. approval for Idefirix for highly sensitized kidney transplant patients
Read More
FDA approves Winlevi for acne
Read More
New phase II study investigates pelareorep with retifanlimab for triple-negative breast cancer
Read More
